MedTrace Logo

CETI-ANKLE: Cetilar®️ in Patients With Ankle Injury or Chronic Trauma to the Ankle

NCT06137820 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-11-18

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and efficacy of Cetilar®

Conditions

  • Ankle Injury or Chronic Trauma to the Ankle

Interventions

DEVICE

Cetilar® (topical cream)

Topical cream twice daily for 30 days. An average amount of 5 g per day.

DEVICE

Cetilar Placebo

Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day

Sponsors & Collaborators

  • NEA Clinical S.r.l.

    collaborator UNKNOWN

  • Pharmanutra S.p.a.

    lead INDUSTRY

Principal Investigators

  • Maria Sole Rossato · Pharmanutra S.p.a.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-18
Primary Completion
2023-08-19
Completion
2023-12-31

Countries

  • Georgia
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137820 on ClinicalTrials.gov